Group 1 - Sileck's subsidiary received a project designation letter from a South Korean battery customer, expected to supply approximately 360 million cylindrical battery shells from 2027 to 2031 [1] - Fuguang Co.'s major shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 481.68 million shares [2] - Beixin Road and Bridge's consortium won a contract for a project worth 1.145 billion yuan, with two segments valued at 223.1 million yuan and 921.5 million yuan respectively [3] Group 2 - Jianyou Co.'s subsidiary received FDA approval for sodium selenite injection, aimed at providing selenium for parenteral nutrition in adults and pediatric patients [4] - China Galaxy received approval to publicly issue subordinated bonds totaling up to 20 billion yuan [6] - Changjiang Electric Power announced a cash dividend of 0.21 yuan per share, totaling 5.138 billion yuan [7] Group 3 - Zhongjin Company received approval to publicly issue corporate bonds totaling up to 20 billion yuan [8] - Daon Co. received a decision from the State Administration for Market Regulation not to conduct further antitrust review on its acquisition of Ningbo Aisikai Synthetic Rubber Co. [10] - Palm Co. won a project worth approximately 228 million yuan, which is expected to account for 7.44% of its audited revenue for 2024 [11] Group 4 - Kang En Bei's subsidiary received approval for clinical trials of TFA003 tablets for diabetic nephropathy [13] - Xinmai Medical's subsidiary obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres [14] - Guangsheng Tang's innovative hepatitis B drug completed the enrollment of 578 participants in its Phase III clinical trial [15] Group 5 - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [16] - Liya De plans to invest up to 100 million yuan in an industry fund focused on commercial aerospace [17] - Zhongwen Online plans to collaborate with Tencent on animation micro-short drama licensing, with an expected cooperation amount of 23.2 million yuan [19] Group 6 - Yungsheng Technology is planning to acquire control of Fengrui Fluorine Industry, with its stock continuing to be suspended [22] - Yinbang Co. received a sales order from HOLTEC ASIA for approximately 280 million yuan, expected to positively impact its operations in 2026 and 2027 [23] - Pailin Bio's subsidiary received a drug registration acceptance notice for human coagulation factor IX [24] Group 7 - Dao Dao Quan plans to apply for soybean oil delivery warehouse qualifications from the Dalian Commodity Exchange [25] - Qizheng Tibetan Medicine's subsidiary received a registration certificate for a traditional Chinese medicine product in Macau [26] - Vili Medical received EU MDR certification for multiple products [27][28] Group 8 - CITIC Bank plans to increase its investment in its wholly-owned subsidiary by 2 billion yuan [29] - Hayao Co. received approval for the consistency evaluation of its injectable drugs [30] - Zhifei Biological's freeze-dried varicella vaccine clinical trial received approval [31] Group 9 - Huibo Pu signed a contract worth 225 million USD for the Naft Khana oilfield recovery project [32] - Zhonggu Logistics plans to invest in the construction of two 6000 TEU container ships, with a total contract amount not exceeding 1.16 billion yuan [33] - Chongqing Beer reported a 10.43% increase in net profit for 2025, with revenue of 14.722 billion yuan [34] Group 10 - Huanxu Electronics reported a 12.16% increase in net profit for 2025, with revenue of 59.195 billion yuan [35] - Chengzhi Co.'s subsidiary successfully completed trial production of a high molecular weight polyethylene project [36] - Guangyang Co. signed a strategic cooperation agreement with Shenzhen Xuanchuang and Huangshan Guangyang [37]

Investment Rating - The industry investment rating is "Outperform the Market" (maintained) [1][38] Core Viewpoints - The industry is experiencing profound changes in funding structure, leading to a shift towards reallocation rather than trading. The continuous expansion of passive indices has brought stable capital inflows, and the high dividend yield of the banking sector, currently averaging 4.50%, is attracting long-term funds such as insurance capital. Regulatory measures aimed at guiding long-term capital into the market are expected to sustain the attractiveness of dividend allocation value [2][10] - The 2025 annual performance reports indicate a recovery in revenue and profit, with asset quality showing steady improvement. As of the end of January, ten banks reported their 2025 performance, with most showing a year-on-year increase in revenue and profit. Notably, Qingdao Bank, Nanjing Bank, and Shanghai Pudong Development Bank maintained high growth rates in net profit and revenue, with growth rates of 21.7%, 8.1%, and 10.5% respectively [3][6][7] Summary by Sections Performance Overview - Revenue and profit are recovering, with asset quality improving. The average year-on-year growth rate of net profit for the ten banks is 7.2%, with a quarter-on-quarter increase of 0.6 percentage points. The average non-performing loan (NPL) ratio decreased by 2 basis points to 0.94% [6][7][8] - The average loan growth rate for the ten banks increased from 10.1% in the first three quarters of 2025 to 15.5% for the full year, indicating a positive loan issuance trend [6][7] Market Trends - In January 2026, the banking sector declined by 6.18%, underperforming the CSI 300 index by 7.83 percentage points, ranking last among 30 sectors [14] - Individual bank performances varied, with Qingdao Bank, Ningbo Bank, and Hangzhou Bank showing increases of 16.5%, 10.2%, and 5.8% respectively [15] Macro and Liquidity Tracking - The manufacturing PMI for January was 49.30%, a decrease of 0.80 percentage points from the previous month. The CPI for December was 0.80% year-on-year, while the PPI was -1.90% [25][22] - In January, the one-year and five-year LPR remained stable at 3.0% and 3.50% respectively. The interbank lending rates for 7D, 14D, and 3M changed to 1.61%, 1.68%, and 1.78% respectively [28][26] Credit and Social Financing Data - In December 2025, new RMB loans increased by 910 billion, a year-on-year decrease of 80 billion, with a balance growth rate of 6.40%. Corporate loans increased by 1.07 trillion, while household loans decreased by 91.6 billion [29][32] - The social financing scale increased by 2.21 trillion in December, with a year-on-year growth rate of 8.30% [32]

公司名稱: 中信銀行股份有限公司(「本行」) 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 FF301 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 601998 | 說明 | A股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 40,762,999,287 | RMB | | 1 RMB | | 40,762,999,287 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 40,762,999,287 | RMB | | 1 RMB | | 40,762,999,287 | | 3. 股份分類 | 優先股 | 股份類別 | 其他類別 (請註明) | ...

Core Viewpoint - CITIC Bank plans to increase its investment in its wholly-owned subsidiary, CITIC Financial Leasing Co., Ltd., by 2 billion RMB, raising the subsidiary's registered capital from 10 billion RMB to 12 billion RMB [1] Financial Performance - As of the end of 2024, CITIC Financial Leasing's total assets amounted to 83.419 billion RMB, with total liabilities of 74.348 billion RMB and net assets of 9.071 billion RMB, resulting in a debt-to-asset ratio of 89.13% [1] - For the year 2024, CITIC Financial Leasing reported an operating net income of 1.697 billion RMB and a net profit of 936 million RMB [1] - By September 30, 2025, the total assets of CITIC Financial Leasing are projected to reach 112.928 billion RMB, with total liabilities of 99.671 billion RMB and net assets of 13.258 billion RMB, leading to a debt-to-asset ratio of 88.26% [1] - From January to September 2025, the company is expected to achieve an operating net income of 1.664 billion RMB and a net profit of 1.184 billion RMB [1]

Group 1 - The banking sector saw an increase of 1.51% on February 4, with China Merchants Bank leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] - Key stocks in the banking sector showed various performance metrics, with China Merchants Bank closing at 39.01, up 1.85%, and CITIC Bank at 7.35, up 1.66% [1] Group 2 - The banking sector experienced a net inflow of 1.133 billion yuan from main funds, while retail and speculative funds saw net outflows of 0.351 billion yuan and 0.782 billion yuan, respectively [1] - Major banks like China Merchants Bank and Industrial Bank had significant net inflows of 1.642 billion yuan and 0.322 billion yuan, respectively, indicating strong institutional interest [1] - In contrast, banks like Everbright Bank and CITIC Bank faced net outflows of 0.549 billion yuan and 0.239 million yuan, reflecting weaker retail sentiment [1]

Core Viewpoint - CITIC Bank Zhengzhou Branch is enhancing its role as a leading "foreign exchange service bank" by providing integrated financial services to support Chinese enterprises in cross-border mergers and acquisitions, cross-border settlements, and foreign exchange risk management [1] Group 1: Financial Services - Recently, CITIC Bank Zhengzhou Branch issued a USD 40 million cross-border merger loan to assist a company in expanding its operations internationally, aligning with national strategic resource globalization [1] - The bank leverages the comprehensive financial capabilities of CITIC Group to offer "financing + intelligence" integrated services tailored to meet enterprise needs [1] Group 2: Operational Efficiency - The bank has established a green approval channel that allows for project initiation in one day and credit approval completion within one week, making it the first domestic bank to receive such approval [1] - CITIC Bank Zhengzhou Branch provides document preparation solutions that reduce operational difficulties and professional barriers for enterprises, particularly benefiting small and medium-sized foreign trade companies [1] Group 3: Future Outlook - The bank plans to continuously optimize its cross-border financial service system to provide more professional, efficient, and comprehensive financial services, supporting the stable and sustainable development of foreign trade enterprises [1]

格隆汇2月4日丨中信银行(00998.HK)发布公告，本行拟使用自有资金向全资子公司中信金融租赁有限公 司(以下简称中信金租)现金增资人民币20亿元。本次增资完成后，中信金租注册资本将由人民币100亿 元增加至120亿元，本行仍持有中信金租100%股权。 ...

中信银行（601998）(00998)发布公告，2026年2月4日，本行以现场会议方式召开的第七届董事会第二 十一次会议审议通过了《关于中信金融租赁有限公司资本补充方案的议案》，该议案有效表决票9票， 表决结果：赞成9票、反对0票、弃权0票。根据董事会会议决议，董事会同意本行使用自有资金向中信 金租现金增资人民币20亿元。本次增资完成后，中信金租注册资本将由人民币100亿元增加至120亿元， 本行仍持有中信金租100%股权。 本次增资不存在损害本行及本行全体股东利益的情形，且对本行持续经营能力、损益及资产状况不构成 重要影响。中信金租是本行服务实体经济的重要战略布局，本次增资将助力中信金租把握发展机遇，加 快业务发展，提升市场竞争力和影响力，进一步为银行集团的持续发展创造价值。 ...

智通财经APP讯，中信银行(00998)发布公告，2026年2月4日，本行以现场会议方式召开的第七届董事会 第二十一次会议审议通过了《关于中信金融租赁有限公司资本补充方案的议案》，该议案有效表决票9 票，表决结果：赞成9票、反对0票、弃权0票。根据董事会会议决议，董事会同意本行使用自有资金向 中信金租现金增资人民币20亿元。本次增资完成后，中信金租注册资本将由人民币100亿元增加至120亿 元，本行仍持有中信金租100%股权。 本次增资不存在损害本行及本行全体股东利益的情形，且对本行持续经营能力、损益及资产状况不构成 重要影响。中信金租是本行服务实体经济的重要战略布局，本次增资将助力中信金租把握发展机遇，加 快业务发展，提升市场竞争力和影响力，进一步为银行集团的持续发展创造价值。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中信銀行股份有限公司(「本行」) 呈交日期: 2026年2月4日 FF301 | | 法定/註冊股份數目 | 面值 | | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | --- | | 上月底結存 | 350,000,000 | RMB | | 100 RMB | | 35,000,000,000 | | 增加 / 減少 (-) | | | | RMB | | | | 本月底結存 | 350,000,000 | RMB | | 100 RMB | | 35,000,000,000 | | | | 本月底法定/註冊股本總額： | RMB | | 90,645,162,264 | | 備註： 1.優先股不計入本行注冊股本。 第 2 頁 共 12 頁 v 1.2.0 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1 ...